Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Serono completes enrolment for cilengitide trial

Merck Serono completes enrolment for cilengitide trial

10th June 2011

Merck Serono has completed enrolment for a new phase III clinical trial that will evaluate the investigational drug cilengitide against glioblastoma.

More than 500 patients have been successfully recruited to take part in the global Centric trial, which will compare the safety and efficacy of the drug in combination with standard treatment among a specific subgroup of newly diagnosed patients.

The primary endpoint of the study is overall survival improvements, with cilengitide controlling tumour growth both through direct attack and by preventing the formation of new blood cells to feed the tumour.

Cilengitide is the first integrin inhibitor, a new class of investigational anti-cancer therapies, to successfully reach phase III development.

Dr Oliver Kisker, senior vice-president for Merck Serono's global oncology clinical development unit, said: "Completing patient enrolment in the Centric study … takes us a step closer to evaluating the efficacy and safety of cilengitide in patients with this aggressive form of brain cancer."

Earlier this week, the company announced a new alliance with Affectis Pharmaceuticals that will see the companies developing new treatments for neurodegenerative disease.ADNFCR-8000103-ID-800574532-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.